Drugs News and Research

RSS

Amarin completes patient randomization in AMR101 Phase 3 trial in patients with high triglyceride levels

Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported the completion of patient randomization for its ANCHOR trial, a pivotal Phase 3 trial of AMR101. The Company indicated that it anticipates reporting top-line results from this trial in Q2 2011.

16 Dec 2010

PCSBI issues 18 recommendations in emerging field of synthetic biology

The Presidential Commission for the Study of Bioethical Issues today released its first report-a wide-ranging review of the emerging field of synthetic biology-issuing 18 recommendations including a call for coordinated federal oversight of scientists working in both large institutions and smaller settings.

16 Dec 2010

Boehringer Ingelheim's selection of development candidate triggers € 6.5 million milestone payment to Orexo

Orexo AB and Boehringer Ingelheim announced today that Boehringer Ingelheim has selected a development candidate resulting from the worldwide exclusive research, development and commercialisation agreement which Boehringer Ingelheim had signed in November 2005 with Biolipox, a Swedish research-based pharmaceutical company acquired by Orexo in October 2007.

16 Dec 2010

Study describes CC3/TIP30 protein regulate metabolic adaptation of tumor cells to glucose limitation

Bionovo, today announced the publication of a study entitled "CC3/TIP30 regulates metabolic adaptation of tumor cells to glucose limitation" in the journal Cell Cycle.

16 Dec 2010

Systematic study on protein-protein interfaces explain "promiscuous" phenomena of its binding

Interactions between proteins are at the heart of cellular processes, and those interactions depend on the interfaces where the direct physical contact occurs. A new study published this week suggests that there may be roughly a thousand structurally-distinct protein-protein interfaces - and that their structures depend largely on the simple physics of the proteins.

16 Dec 2010

New finding sheds light on how HIV eludes treatment by mutating

The virus that causes AIDS is chameleon-like in its replication. As HIV copies itself in humans, it constantly mutates into forms that can evade even the best cocktail of current therapies. Understanding exactly how HIV cells change as they reproduce is key to developing better tests and treatments for patients.

16 Dec 2010

Synthetic derivative of curry spice can be effective neuroprotective for stroke and TBI

A synthetic derivative of the curry spice turmeric, made by scientists at the Salk Institute for Biological Studies, dramatically improves the behavioral and molecular deficits seen in animal models of ischemic stroke and traumatic brain injury.

16 Dec 2010

Ocera completes two studies of OCR-002 in patients with hyperammonemia, hepatic encephalopathy

Ocera Therapeutics, Inc. announced today that it has completed two studies evaluating the safety and pharmacokinetics of OCR-002 (ornithine phenylacetate) which includes healthy volunteers and patients with liver cirrhosis. OCR-002 recently received Orphan Drug status and Fast Track designation by the United States Food and Drug Administration for the treatment of hyperammonemia (excessive ammonia levels) and resultant Hepatic encephalopathy.

16 Dec 2010

AmoyDx receives SFDA approval for its EGFR and BRAF mutations detection kits

Amoy Diagnostics announced today that its EGFR and BRAF mutation detection kits received market approval from China's State Food and Drug Administration (SFDA). The SFDA is the competent authority for regulating drugs and in vitro diagnostics in mainland China. The approval allows AmoyDx to market the EGFR and BRAF tests for clinical use in China.

15 Dec 2010

Clinical Investigation – ground-breaking new launch from Future Science

In recognition of the methodology, progress and outcome of clinical trials, Future Science has announced the launch of the definitive title Clinical Investigation. The journal is the latest addition to the Future Science’s collection of titles addressing those areas that most impact our daily lives (available at www.future-science.com). Future Science is part of London-based Future Science Group.

15 Dec 2010

Targeting mutant BRAF can kill cancer cells, but cannot finish off melanoma

This past summer saw a revolution in melanoma therapy. Patients whose melanoma lesions contain a mutation in the BRAF gene were successfully treated with a BRAF-specific inhibitor, PLX4032. Reports of the drug trial described shrinking tumors and improved health. Yet seven months after therapy began the tumors returned and resumed growing. Now, scientists at The Wistar Institute explain why: the tumor learns to signal around the blocked gene by adjusting its molecular wiring.

15 Dec 2010

Lung protective strategy after brain death doubles lungs eligible for donation

Use of certain measures for lung preservation after brain death in potential organ donors resulted in a nearly doubling of lungs eligible for donation, compared to a conventional strategy that is used, according to preliminary research published in the December 15 issue of JAMA.

15 Dec 2010

MDMA produces friendliness, playfulness, and loving feelings in laboratory setting

MDMA or 'ecstasy' increases feelings of empathy and social connection. These 'empathogenic' effects suggest that MDMA might be useful to enhance the psychotherapy of people who struggle to feel connected to others, as may occur in association with autism, schizophrenia, or antisocial personality disorder.

15 Dec 2010

RPCI forms Photolitec to develop photosensitizing compounds used in photodynamic therapy

Roswell Park Cancer Institute (RPCI) on December 13, 2010, announced the formation of Photolitec, LLC, a new life-sciences company at RPCI that will develop photosensitizing compounds used in photodynamic therapy (PDT). PDT is an innovative cancer treatment pioneered at RPCI by scientist Thomas J. Dougherty, Chief Emeritus of the Institute's Photodynamic Therapy Center.

15 Dec 2010

African sleeping sickness parasite's previously unrecognized extreme social behavior discovered

Long considered a freewheeling loner, the Trypanosoma brucei parasite responsible for African sleeping sickness has revealed a totally unexpected social side, opening a potential chink in the behavioral armor of this and other supposedly solitary human parasites, according to research presented at the American Society for Cell Biology's 50th Annual Meeting in Philadelphia.

15 Dec 2010

Domainex wins 2010 Genesis Life Science Innovation and Enterprise Programme Of The Year Award

Domainex Ltd, the leading UK-based drug discovery CRO, has won the 2010 Genesis Life Science Innovation and Enterprise Programme Of The Year Award. This Award was made in recognition of Domainex's proactive work on promoting academic-industry collaborations, and was adjudicated by leading representatives of the biotechnology and pharmaceutical industries.

From Domainex 15 Dec 2010

Drugs News and Research

Amarin completes patient randomization in AMR101 Phase 3 trial in patients with high triglyceride levels

PCSBI issues 18 recommendations in emerging field of synthetic biology

Boehringer Ingelheim's selection of development candidate triggers € 6.5 million milestone payment to Orexo

Study describes CC3/TIP30 protein regulate metabolic adaptation of tumor cells to glucose limitation

Systematic study on protein-protein interfaces explain "promiscuous" phenomena of its binding

New finding sheds light on how HIV eludes treatment by mutating

Synthetic derivative of curry spice can be effective neuroprotective for stroke and TBI

Ocera completes two studies of OCR-002 in patients with hyperammonemia, hepatic encephalopathy

AmoyDx receives SFDA approval for its EGFR and BRAF mutations detection kits

Clinical Investigation – ground-breaking new launch from Future Science

Targeting mutant BRAF can kill cancer cells, but cannot finish off melanoma

Lung protective strategy after brain death doubles lungs eligible for donation

MDMA produces friendliness, playfulness, and loving feelings in laboratory setting

RPCI forms Photolitec to develop photosensitizing compounds used in photodynamic therapy

African sleeping sickness parasite's previously unrecognized extreme social behavior discovered

Domainex wins 2010 Genesis Life Science Innovation and Enterprise Programme Of The Year Award

Yorkshire Cancer Research to grant over GBP1.26 million for research at universities of Leeds and Sheffield

Researchers examine expression of toxic mRNA in patients with Fragile X Tremor Ataxia Syndrome

Global Fund to draw up action plan against drug theft, invites stakeholders to participate

Naltrexone may help treat alcoholism

Drug Discovery - Second Edition eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News